ReviewEpigenomics2025
Targeting Tudor domains in leukemia: epigenetic insights for drug development.
Review in Epigenomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural basis for the extended-spectrum antimicrobial activity of Garvieacin Q.Applied and environmental microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Leukemia is a heterogeneous group of hematological malignancies characterized by uncontrolled proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Epigenetic dysregulation is one of the critical drivers of leukemogenesis, often involving aberrant activity of chromatin-interacting proteins, such as readers, writers, and erasers. Tudor domain-containing proteins, such as SGF29, JMJD2A, 53BP1, Spindlin1, and UHRF1, play pivotal roles in leukemia progression by controlling key processes such as DNA damage response, transcriptional regulation, and RNA metabolism. Several recent efforts have aimed at pharmacologic targeting of the Tudor domain, opening a novel avenue for targeting epigenetic dysregulation. The review explores the structural characteristics of various Tudor domains, their binding preferences for specific histone modifications, and the consequences of these interactions for leukemia. By providing a comprehensive overview of current research, this review underscores the therapeutic potential of Tudor domain-targeting strategies in leukemia and emphasizes the need for further development of epigenetics-based treatment strategies to address resistance and relapse in these malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.